By removing barriers holding back the increased use of biosimilars, savings could be significant. In a case study of infliximab, used to treat rheumatoid arthritis, Crohn’s disease, and other illnesses, reforms could realize an annual savings of between $412 million and $465 million....
Patients could save time and money if federal law is reformed to allow pharmacists to administer all CDC recommended vaccines. Right now, pharmacists are subject to a patchwork of laws in each state that are effectively barriers to vaccines being administered at neighborhood pharmacies. This access barrier exists even though pharmacists receive vaccination training in their pharmacy school education....
The 340B program, which was created to give discounted prescription drugs to poor Americans, is riddled with abuse. The program has created a perverse incentive for providers to profit instead of effectively serve the poor and is hurting overall health care quality....
This brief explores a tool that millions of Americans use every day when paying for prescription drugs, Pharmacy Benefit Managers, or PBMs, which impact prescription drug costs, access, and patient care. ...
A more realistic evaluation of U.S. prescription drug prices shows that high drug prices are not actually driving up health care costs overall and reflect the higher U.S. health care costs compared to the rest of the world....
Responding to the problem of drug-resistant infections and the decline in the development of new antibiotics, this study explores ways to incentivize the development of new treatments that will effectively address this growing public health crisis....
The study examines the market forces influencing the often dramatic price differences in pharmaceutical drugs before and after their patents expire....